title: [Study on adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) for renal cell carcinoma--amplification of IL-2-elicited TIL proliferation by OKT3-monoclonal antibody].
abstract: Human autologous peripheral blood lymphocytes (PBL) and lymphocytes infiltrating renal cell carcinoma (TIL) were cultured with medium containing 1000 IU/ml of human interleukin 2 (IL-2). A high cytotoxic activity against fresh autologous as well as cultured allogenic tumor cells was developed. By culturing these lymphocytes with OKT3 monoclonal antibody during the initial 2 days of long-term culture, in terms of T cell activation signal, IL-2-driven lymphocyte proliferation was remarkably accelerated with maintenance of appreciable level of cytotoxic activity. The same culture method also induced an increase in OKT3 and IL-2 receptor positive lymphocyte population in LAK cells and TIL. This method may enable us to gain more autologous TIL in vitro for adoptive immunotherapy of renal cell carcinoma than the usual culture method with IL-2 alone. Five patients with metastatic renal cell carcinoma were treated with adoptive immunotherapy with TIL, LAK and IL-2. One patient with pulmonary metastasis has had a minor response which has lasted for 3 months so far. We have not experienced any serious side effects during the treatment.
authors.affiliation: Department of Urology, School of Medicine, University of the Ryukyus.
authors.forename: M
authors.initials: M
authors.lastname: Hayakawa
authors.forename: S
authors.initials: S
authors.lastname: Sisido
authors.forename: I
authors.initials: I
authors.lastname: Higa
authors.forename: Y
authors.initials: Y
authors.lastname: Koyama
authors.forename: T
authors.initials: T
authors.lastname: Hatano
authors.forename: A
authors.initials: A
authors.lastname: Osawa
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D002455:Cell Division; D002478:Cells, Cultured; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation; D008213:Lymphocyte Activation; D017710:Lymphocyte Transfusion
chemical_list: D000911:Antibodies, Monoclonal; D007376:Interleukin-2